

CLAIMS

1. Biologically active isolated Tat protein, fragments thereof and/or mutants and/or Tat DNA for use as a vaccine, said Tat, at picomolar to nanomolar concentrations being capable of: (i) entering and localizing in the nuclei of activated endothelial cells or dendritic cells; and/or (ii) activating the proliferation, migration and invasion of Kaposi's sarcoma (KS) cells and cytokine-activated endothelial cells protein.
2. Biologically active isolated Tat protein, fragments thereof and/or mutants and/or DNA Tat according to claim 1 further capable of: (iii) activating virus replication when added to infected cells as measured a) by the rescue of Tat-defective proviruses in HLM-1 cells after the addition of exogenous protein; and/or b) by the transactivation of HIV-1 gene expression in cells transfected with a HIV-1 promoter-reporter plasmid.
3. Biologically active isolated Tat protein, fragments thereof and/or mutants and/or Tat DNA according to claim 2 further capable of: (iv) inducing in mice the development of KS-like lesions in the presence of angiogenic factors or inflammatory cytokines.
4. Biologically active isolated Tat protein, fragments thereof and/or mutants and/or Tat DNA according to claims 1-3 at amounts ranging between 10 ng/ml and 1 µg/ml.
5. Biologically active isolated Tat protein, fragments thereof and/or mutants and/or Tat DNA according to claims 1-4 for use in the prophylactic and/or therapeutic treatment of AIDS, tumors, syndromes and symptoms associated with HIV infection.
6. Protein or peptide or DNA vaccine, prophylactic and/or therapeutic, against AIDS, AIDS-associated tumors, syndromes and symptoms associated with the HIV infection, comprising biologically active Tat and/or its mutants and/or portion of the protein or peptides or a DNA as defined in claims 1-4.
7. Vaccine according to claim 6 in which Tat has the following nucleotide sequence (Seq.1) :

5'ATGGAGCCAGTAGATCCTAGACTAGAGCCCTGGAAGCATCCAGGAAGTC
AGCCTAAACTGCTTGTACCAATTGCTATTGTAAAAAGTGTTGCTTTCATTG

AMENDED SHEET

CCAAGTTTGTTCATAACAAAAGCCTTAGGCATCTCCTATGGCAGGAAGAA
GCGGAGACAGCGACGAAGACCTCCTCAAGGCAGTCAGACTCATCAAGTTT
CTCTATCAAAGCAGCCCACCTCCCAATCCCGAGGGGACCCGACAGGCC
GAAGGAATAG 3'

5 and any other Tat variant of any HIV type and subtype.

8. Vaccine according to ~~claim 6~~ in which Tat has the following amino acid
sequence:

NH₂-MEPVDPRIEPAWKHPGSQPKTACTNICYCKKCCFHCQVGFHKALGISY
GRKKRRORRRPQGSQTHQVSLSKQPTSQSRGDPTEPKE-COOH

10 and any other Tat variant of any HIV type and subtype.

9. Vaccine according to claim 6 in which mutants are selected among the ones
having the following nucleotide sequences or part of them:

Nucleotide sequence of cys22 mutant (Seq.2)

5'ATGGAGCCAGTAGATCCTAGACTAGAGCCCTGGAAGCATCCAGGAAGTCA
15 GCCTAAAACTGCGGTACCAATTGCTATTGTAAAAAGTGTTGCTTTTCATTGC
CAAGTTTGTTCATAACAAAAGCCTTAGGCATCTCCTATGGCAGGAAGAA
GCGGAGACAGCGACGAAGACCTCCTCAAGGCAGTCAGACTCATCAAGTT
TCTCTATCAAAGCAGCCCACCTCCCAATCCCGAGGGGACCCGACAGGCC
CGAAGGAATAG 3'

20 Nucleotide sequence of lys41 (Seq.3)

5'ATGGAGCCAGTAGATCCTAGACTAGAGCCCTGGAAGCATCCAGGAAGTCA
GCCTAAAACTGCTTGTACCAATTGCTATTGTAAAAAGTGTTGCTTTTCATTG
CCAAGTTTGTTCATAACAAACGCCTTAGGCATCTCCTATGGCAGGAAGA
AGCGGAGACAGCGACGAAGACCTCCTCAAGGCAGTCAGACTCATCAAGT
25 TTCTCTATCAAAGCAGCCCACCTCCCAATCCCGAGGGGACCCGACAGGC
CCGAAGGAATAG 3'

Nucleotide sequence of RGD Δ mutant (Seq.4)

5'ATGGAGCCAGTAGATCCTAGACTAGAGCCCTGGAAGCATCCAGGAAGTCA
GCCTAAAACTGCTTGTACCAATTGCTATTGTAAAAAGTGTTGCTTTTCATTG
30 CCAAGTTTGTTCATAACAAAAGCCTTAGGCATCTCCTATGGCAGGAAGA
AGCGGAGACAGCGACGAAGACCTCCTCAAGGCAGTCAGACTCATCAAGT
TTCTCTATCAAAGCAGCCCACCTCCCAATCCCGACAGGCCCGAAGGAAT

AG 3'

Nucleotide sequence of lys41-RGDΔ mutant (Seq.5)

5'ATGGAGCCAGTAGATCCTAGACTAGAGCCCTGGAAGCATCCAGGAAGTCA
 GCCTAAAACTGCTTGTACCAATTGCTATTGTAAAAAGTGTTGCTTTCATTG
 5 CCAAGTTTGTTCATAACAAACGCCTTAGGCATCTCCTATGGCAGGAAGA
 AGCGGAGACAGCGACGAAGACCTCCTCAAGGCAGTCAGACTCATCAAGT
 TTCTCTATCAAAGCAGCCCACCTCCCAATCCCCGACAGGCCCGAAGGAAT
 AG 3'

10.Vaccine according to claim 6 in which mutants are selected among the ones
 10 having the following amino acid sequence or part of them:

Amino acid sequence of cys22 mutant

NH₂-MEPVDPRLEPWKHPGSQPKTAGTNCYCKKCCFHCQVCFITKA
 LGISYGRKKRRRQRRRPPQGSQTHQVSLSKQPTSQSRGDPTGPKE-COOH

Amino acid sequence of lys41

15 NH₂-MEPVDPRLEPWKHPGSQPKTACTNCYCKKCCFHCQVCFITTAL
 GISYGRKKRRRQRRRPPQGSQTHQVSLSKQPTSQSRGDPTGPKE-COOH

Amino acid sequence of RGDΔ mutant

NH₂-MEPVDPRLEPWKHPGSQPKTACTNCYCKKCCFHCQVCFITKAL
 GISYGRKKRRRQRRRPPQGSQTHQVSLSKQPTSQSPTGPKE-COOH

Amino acid sequence of lys41-RGDΔ mutant

20 NH₂-MEPVDPRLEPWKHPGSQPKTACTNCYCKKCCFHCQVCFITTAL
 GISYGRKKRRRQRRRPPQGSQTHQVSLSKQPTSQSPTGPKE-COOH

11.Vaccine according to claim 6 in which the Tat portions are selected among the
 peptide sequences

Pep. 1. MEPVDPRLEPWKHPGSQPKT

Pep. 2. ACTNCYCKKCCFHCQVCFIT

Pep. 3. QVCFITKALGISYGRK

Pep. 4. SYGRKKRRRQRRRPPQ

Pep. 5. RPPQGSQTHQVSLSKQ

30 Pep. 6. HQVSLSKQPTSQSRGD

Pep. 7. PTSQSRGDPTGPKE

12.Vaccine according to claims 6-11 comprising proteins or peptides conjugated

with the T-helper universal epitope of Tetanus toxoid or any T-helper peptides.

13. Vaccine according to claims 6-12 in combination with recombinant proteins or peptides of HIV Nef, Rev or Gag or part of them.

14. Vaccine according to claim 6 comprising fusion proteins Tat (wild type or its mutants)/Nef, Tat (wild type or its mutants)/Rev, Tat (wild type or its mutants)/Gag or part of them.

15. Vaccine according to claim 6-14 in combination with recombinant immuno-modulant cytokines or other molecules or part of them, augmenting antiviral immune response.

16. Vaccine according to claim 15 in which cytokines are IL-12 and/or IL-15 or IFN α or IFN β .

17. Vaccine according to claim 6 comprising fusion proteins Tat(wild type or its mutants)/immuno-modulant cytokines, Tat (wild type or its mutants)/IL-12, Tat (wild type or its mutants)/IL-15, Tat (wild type or its mutants)/other molecules, or part of them, augmenting the antiviral immune response.

18. DNA vaccine according to claims 6, 7, 9 comprising DNA encoding for Tat wild-type or its mutants or part of them, inserted in expression vectors.

19. DNA vaccine according to claims 6, 7, 9 in combination with an expression vector including HIV rev, nef and gag genes, or part of them.

20. DNA vaccine according to claims 18 or 19 in which the vector is a plasmid co-expressing tat (wild-type or its mutants)/rev, tat (wild-type or its mutants)/nef, tat (wild-type or its mutants)/gag or part of them.

21. DNA vaccine according to claims 6, 7, 9 in combination with DNA molecules inserted in expression vectors encoding for immuno-modulant cytokines or other immuno-modulant molecules, or part of them, augmenting the antiviral immune response.

22. DNA vaccine according to claim 21 in which the cytokine is IL-12 and/or IL-15.

23. DNA vaccine according to claims 21 or 22 in which the vector is a plasmid co-expressing tat (wild-type or its mutants)/IL-12, tat (wild-type or its mutants)/IL-15, tat (wild-type or its mutants)/other molecules, or part of them, able to augment the antiviral immune response.

24. Vaccine according to claims 18-23 in which the vector is pCV0.

25. Vaccine according to claims 6-24 including autologous dendritic cells treated and/or untreated according to the previous claims.

26. Vaccine according to claims 6-25 including adjuvants able to augment the antiviral immune response.

27. Vaccine according to claim 26 in which the adjuvant is selected among Alum, ISCOM, RIBI and corresponding mixtures.

28. Vaccine according to claims 6-27 comprising systems for delivery.

29. Vaccine according to claim 28 in which the systems for delivery are selected among nanoparticles, herpes vectors, red cells, bacteria and combinations thereof.

30. Vaccine according to claim 29 in which bacteria are selected among *Streptococcus gordonii* and *Lactobacillus*.

31. Vaccine according to claims 29 and 30 in which bacteria are modified to express viral antigens.

32. Vaccine according to claims 6-31 for the immunization of peripheral blood cells from infected individuals, expanded by co-stimulation with magnetic beads coated with anti-CD3 and anti-CD28 antibodies.

33. Therapeutic vaccine according to claims 6-32, combined with inhibitors of viral replication.

34. Vaccine according to claims 6-33 in which the active principle is delivered to the mucosa.

35. Vaccine according to claim 34, in which the active principle is administered nasally, orally, vaginally and/or rectally.

36. Vaccine according to claims 6-33 in which the active principle is administered through systemic or local route.

37. Vaccine according to claim 36 in which the active principle is administered through intramuscular, subcutaneous or intradermal route.

38. Vaccine according to claim 37 in which the active principle is administered intradermally at 1-6 μ g amounts, without adjuvants.

39. Vaccine according to claims 34-38 in which the active principle is carried in a biologically acceptable fluid.

40. Vaccine according to claims 34-39 further comprising pharmaceutically

acceptable carriers and eccipients to maximize the principle activity.

41. Vaccine according to claims 34-40 comprising as active principle Tat according to claim 1 at preventive and/or therapeutic amounts.

42. Biologically active Tat mutant protein having nucleotide sequence selected among:

Nucleotide sequence of the cys22 mutant (Seq.2)

5'ATGGAGCCAGTAGATCCTAGACTAGAGCCCTGGAAGCATCCAGGAAGT
CAGCCTAAAACTGCGGTACCAATTGCTATTGTAAAAAGTGTTGCTTTTCATT
GCCAAGTTTGTTCATAACAAAAGCCTTAGGCATCTCCTATGGCAGGAAG
AAGCGGAGACAGCGACGAAGACCTCCTCAAGGCAGTCAGACTCATCAAG
TTTCTCTATCAAAGCAGCCACCTCCCAATCCCGAGGGGACCCGACAGG
CCCGAAGGAATAG 3'

Nucleotide sequence of the lys41 mutant (Seq.3)

5'ATGGAGCCAGTAGATCCTAGACTAGAGCCCTGGAAGCATCCAGGAAGT
CAGCCTAAAACTGCTTGTACCAATTGCTATTGTAAAAAGTGTTGCTTTTCAT
TGCCAAGTTTGTTCATAACAAACGCCTTAGGCATCTCCTATGGCAGGAA
GAAGCGGAGACAGCGACGAAGACCTCCTCAAGGCAGTCAGACTCATCAA
GTTTCTCTATCAAAGCAGCCACCTCCCAATCCCGAGGGGACCCGACAG
GCCCCGAAGGAATAG 3'

Nucleotide sequence of the RGD Δ mutant (Seq.4)

5'ATGGAGCCAGTAGATCCTAGACTAGAGCCCTGGAAGCATCCAGGAAGT
CAGCCTAAAACTGCTTGTACCAATTGCTATTGTAAAAAGTGTTGCTTTTCAT
TGCCAAGTTTGTTCATAACAAAAGCCTTAGGCATCTCCTATGGCAGGAA
GAAGCGGAGACAGCGACGAAGACCTCCTCAAGGCAGTCAGACTCATCAA
GTTTCTCTATCAAAGCAGCCACCTCCCAATCCCGACAGGCCCGAAGG
AATAG 3'

Nucleotide sequence of the lys41-RGD Δ mutant (Seq.5)

5'ATGGAGCCAGTAGATCCTAGACTAGAGCCCTGGAAGCATCCAGGAAGT
CAGCCTAAAACTGCTTGTACCAATTGCTATTGTAAAAAGTGTTGCTTTTCAT
TGCCAAGTTTGTTCATAACAAACGCCTTAGGCATCTCCTATGGCAGGAA
GAAGCGGAGACAGCGACGAAGACCTCCTCAAGGCAGTCAGACTCATCAA
GTTTCTCTATCAAAGCAGCCACCTCCCAATCCCGACAGGCCCGAAGG

AATAG 3'

43. Biologically active Tat mutants amino acid sequence selected among:

Amino acid sequence of cys22 mutant

NH₂-MEPVDPRLEPWKHPGSQPKTAGTNCYCKKCCFHCQVCFITKA

5 LGISYGRKKRRQRRRPPQGSQTHQVSLSKQPTSQSRGDPTGPKE-COOH

Amino acid sequence of lys41 mutant

NH₂-MEPVDPRLEPWKHPGSQPKTACTNCYCKKCCFHCQVCFITTAL

GISYGRKKRRQRRRPPQGSQTHQVSLSKQPTSQSRGDPTGPKE-COOH

Amino acid sequence of RGDΔ mutant

10 NH₂-MEPVDPRLEPWKHPGSQPKTACTNCYCKKCCFHCQVCFITKAL

GISYGRKKRRQRRRPPQGSQTHQVSLSKQPTSQSPTGPKE-COOH

Amino acid sequence of lys41-RGDΔ mutant

NH₂-MEPVDPRLEPWKHPGSQPKTACTNCYCKKCCFHCQVCFITTAL

GISYGRKKRRQRRRPPQGSQTHQVSLSKQPTSQSPTGPKE-COOH

15 44. Biologically active Tat mutants with peptide sequence selected among :

Pep. 1. MEPVDPRLEPWKHPGSQPKT

Pep. 2. ACTNCYCKKCCFHCQVCFIT

Pep. 3. QVCFITKALGISYGRK

Pep. 4. SYGRKKRRQRRRPPQ

Pep. 5. RPPQGSQTHQVSLSKQ

Pep. 6. HQVSLSKQPTSQSRGD

Pep. 7. PTSQSRGDPTGPKE

45. Expression vector comprising a DNA sequence selected among the ones listed in claim 42 or parts thereof.

25 46. Expression vector pCV0 including a DNA sequence selected among the ones listed in claim 42 or parts thereof.

47. Expression vector pCV0 according to claim 46, comprising a DNA sequence codifying for a gene selected among tat, rev, nef, gag, IL-12, IL-15 and combinations thereof.

30 48. Transformed cells including the vector according to claims 45-47.

49. Use of the pCVO vector modified according to claims 46-47 to make a vaccine preventive and/or therapeutic against AIDS, AIDS-associated tumors, the

syndromes and symptoms associated to HIV infection.

50. Dendritic cells treated with Tat protein or its peptides or mutants according to claims 43 and 44 or combinations with Rev, Nef, and Gag proteins and/or cytokines.

51. Dendritic cells according to claim 49 transduced with an expression vector comprising tat gene.

52. Use of Tat in its non oxidated and non aggregated form for preparing a vaccine according to claims 6-41

53. Use of lyophilized Tat for preparing a vaccine according to claims 6-41, said lyophilized Tat being re-suspended in a biologically acceptable fluid for administration.

54. Use of Tat protein according to claims 1-5 to make a protein or peptide or DNA vaccine, preventive and/or therapeutic, against AIDS, AIDS-associated tumors, the syndromes and symptoms associated to HIV infection.

55. Use of Alum, ISCOM, RIBI and other adjuvants, alone or in combination, to make a vaccine according to claim 6.

56. Use of paramagnetic beads coated with monoclonal antibodies anti-CD3 and anti-CD28 to make a vaccine according to claim 6.

57. Therapeutic method for treating AIDS, AIDS-associated tumors, syndromes and symptoms associated with HIV infection, characterised in that preventive or therapeutic amounts of biologically active Tat according to claims 1-5 are administered.